Comparison of false positive rates for screening breast magnetic resonance imaging (MRI) in high risk women performed on stacked versus alternating schedules

Edress Othman¹, Jue Wang², Brian L Sprague³, Tiffany Rounds¹, YongLi Ji¹, Sally D Herschorn⁴ and Marie E Wood¹*

Abstract

Purpose: Breast MRI added to mammography increases screening sensitivity for high-risk women but false-positive (FP) rates are higher and the optimal screening schedule for coordination with mammography is unclear. We compare rates of FP MRI when studies were performed on two different schedules.

Patients and methods: High-risk women at the University of Vermont who had at least 1 MRI and 1 mammogram performed within one year between 2004–2012 were eligible for inclusion in this study. Screening was considered stacked if both studies were performed within 90 days and alternating if studies were 4–8 months apart. False positive was defined in one of three ways.

Results: 137 women had screening which met inclusion criteria and 371 MRIs were reviewed. The FP rates were similar for the two schedules when considering BI-RAD 4, 5, 0 or biopsy as a positive test. FP rates were significantly higher for the stacked schedule (18.2 vs. 10.2%, p = 0.026) when considering BI-RADS 3-4-5-0 as positive test, due to the elevated rate of BI-RADS 3 assessments among stacked exams.

Conclusion: False positive rates differ based on the type of exam (baseline or subsequent) and definition of positive but do not differ based on imaging schedule (stacked or alternating); suggesting that women and their providers may choose the imaging schedule they prefer. This is significant as a randomized clinical trial comparing the two schedules is not likely to be performed, given the high cost and large number of women needed for such a study.

Keywords: Breast cancer screening; Screening breast MRI; False positive; Screening schedule; High risk

Introduction

The implementation of screening mammography was a major step in the fight against breast cancer, but several studies have demonstrated lower sensitivity of mammography in younger women (Kerlikowske et al. 1993) (Hendrick et al. 1997) and women at increased risk (Kuhl et al. 2005) (Berg et al. 2008). Adding screening breast MRI to mammography for women at increased risk for breast cancer (due to a family history) results in increased sensitivity and decreased interval cancer rates (Brekelmans et al. 2001) (Kriege et al. 2001) (Tilanus-Linthorst et al. 2000) (Kriege et al. 2004) (Weinstein et al. 2009) (Klijn 2010) (Kuhl et al. 2005) (Warner et al. 2004) (Leach et al. 2005). However, the specificity of screening breast MRI is low (79-89%) especially for premenopausal women (Brekelmans et al. 2001) (Kriege et al. 2001) (Tilanus-Linthorst et al. 2000) (Kriege et al. 2004) (Weinstein et al. 2009). This means a high false positive rate which results in additional imaging, biopsy and anxiety in this population (Brekelmans et al. 2001) (Kriege et al. 2001) (Tilanus-Linthorst et al. 2000) (Kriege et al. 2004) (Weinstein et al. 2009).

In 2007, the American Cancer Society (ACS) published recommendations for screening breast MRI in addition to mammography for high risk women which include; all women with a lifetime risk of more than 20% to 25% based on family history, women with BRCA mutation,
first-degree untested relative of BRCA carrier, women with Li-Fraumeni syndrome and first-degree relatives, women with Cowden syndrome and first-degree untested relatives, and women who had radiation to chest wall between ages 10 and 30 (Saslow et al. 2007).

The optimum timing of screening studies (should they be done at the same time as screening mammography ["stacked"] or alternating with one study every six months) has not been addressed. The above mentioned studies demonstrating the increased sensitivity when MRI is added to mammogram specified that imaging studies were done within a short period of time (on the same day or less than 90 days apart). There have been no studies comparing the two screening schedules directly. Identifying the optimal screening schedule may reduce the false positive rates and reduce unnecessary biopsies and imaging. The current study was undertaken to compare the false positive rates for screening breast MRI when imaging is done at the same time each year (a stacked schedule) compared to an every six month imaging (an alternating) schedule.

Patients and methods

Women enrolled in an Institutional Review Board (IRB) approved prospective study of women at moderate and high risk for breast cancer between 2004 and 2012 at the University of Vermont were the subject of this current study. To be eligible to participate in the IRB approved database participants must have an increased risk for developing breast cancer. Patients are identified as having an increased risk for developing breast cancer if they meet any one of the following criteria: A strong family history of breast (male or female) and/or ovarian cancer. Strong family history is defined as one of the following: a. Two or more first-degree relatives with breast cancer or ovarian cancer. b. One first-degree relative and two or more second- or third degree relatives with breast cancer. c. One first-degree relative with breast cancer or ovarian cancer before the age of 50 years. d. One first-degree relative with breast cancer and one or more relatives with ovarian cancer. e. Two second- or third-degree relatives with breast cancer and one or more with ovarian cancer. f. One second- or third-degree relative with breast cancer and two or more with ovarian cancer. g. Three or more second- or third-degree relatives with breast cancer. h. One first-degree relative with bilateral breast cancer. Individuals with a known genetic abnormality of a breast cancer causing gene in themselves or a family member. Individuals with a prior breast biopsy showing atypical ductal hyperplasia or lobular neoplasia (atypical lobular hyperplasia or lobular carcinoma in situ). Individuals with a Gail Model breast cancer risk of greater than or equal to 1.66% over the next 5 years or greater than 20% lifetime risk.

To be included in the current study women must have had at least 1 screening breast MRI and 1 mammogram performed within 1 year. Women were excluded if they had a personal history of invasive breast cancer, had a diagnostic screening breast MRI (i.e., an MRI done to evaluate suspicious lesions on mammography or clinical breast examination, or MRI done as part of work-up for breast cancer) or were using chemoprevention. Medical records were abstracted for clinical, radiological, and biopsy data. One cycle of surveillance was defined as 1 MRI and 1 mammogram done within 1 year. Screening was considered stacked if both studies were performed within 90 days and alternating if studies were 4–8 months apart. Three definitions of a false-positive MRI were considered: 1) MRI result of BI-RADS 4, 5, 0 with no cancer diagnosis within 365 days; 2) BI-RADS 3, 4, 5, 0 with no cancer diagnosis within 365 days; and 3) benign breast biopsy after an MRI-based recommendation.

Dynamic contrast enhanced MRI was performed according to standard techniques (which varied over the time course of the study) and interpreted by breast imaging radiologists with 1–12 years’ experience interpreting breast MRI. The original clinical reports were used in this study. The images were not re-analyzed for research purposes.

Statistics

The analyses were restricted to the 371 MRIs among 137 women which met the above inclusion criteria. Chi-square tests and Fisher’s exact tests were used to compare differences in assessments and false-positive rates between stacked and alternating MRI screens. All statistical analyses were performed using SAS Statistical Software (Version 9.2; SAS Institute, Inc., Cary, North Carolina).

Results

The records of 599 women at increased risk of developing breast cancer and enrolled in the parent database at the University of Vermont from May 1st, 2004 to March 31st, 2012 were reviewed. 440 women did not have a breast MRI as part of their screening, 16 women who had breast MRI performed to evaluate mammographic findings were excluded; an additional 6 women were excluded because they did not have an MRI and mammogram performed within one year. Therefore, 137 women met the inclusion criteria and are the subject of this analysis. See Figure 1 for a consort diagram of study participants. The mean age of women at the time of initial screening breast MRI was 45.8; 78.8% were premenopausal. High risk was attributed to strong family history of breast cancer in 87.6%, BRCA mutation in 18.3%, and prior atypical biopsy in 13.1%. The median number of
surveillance cycles was 2 (range of 1 to 7). Table 1 outlines the characteristics of the participants.

Forty-five women had all screening cycles done on a stacked schedule, 52 women had all cycles done on an alternating schedule, while 40 women had cycles that were mixed with some on a stacked schedule and others on an alternating schedule. 371 screening breast MRIs were reviewed; 165 performed on a stacked and 206 on an alternating schedule. Table 2 reveals the BI-RADS interpretation for MRIs performed on each schedule. There were significantly more BI-RADS category 3 interpretations for MRIs performed on a stacked schedule (9.7 vs. 2.9%, *p = 0.006*). The likelihood of BI-RADS category 4, 5, or 0 interpretation was not significantly different between the two groups (9.7 vs. 8.3%, *p = 0.627*). In addition there were fewer BI-RADS category 1 or 2 interpretations for MRIs performed on a stacked schedule (80.6 vs 88.8%, *p = 0.027*).

The false positive rate was first calculated for MRIs with BI-RADS 4,5,0 interpretations demonstrating a non-significant difference between screening on a stacked or alternating schedule (8.5 vs 7.3% respectively, *p = 0.668*) (Table 3). Defining the false-positive rate for MRIs as BI-RADS 3, 4, 5, 0 interpretation revealed a significant difference between the two screening schedules with 18.2% of MRIs performed on the stacked schedule having a false-positive study compared to 10.2% of MRIs performed on the alternating schedule (*p = 0.026*). Taking into account

### Table 1 Baseline characteristics for women with screening breast MRI

| Characteristic                  | N (%)          |
|---------------------------------|----------------|
| **Demographics**                | 137            |
| Age (mean/range)                | 45.8 (27 – 77) |
| White                           | 135 (98.5%)    |
| Premenopausal                   | 108 (78.8%)    |
| Postmenopausal                  | 29 (21.2%)     |
| **Reason for screening**         |                |
| Family history                  | 120 (87.6%)    |
| BRCA positive                   | 25 (18.2%)     |
| Biopsy with atypia or lobular neoplasia | 18 (13.1%) |
| Prior chest irradiation         | 2 (1.5%)       |

*Note that individual women could have multiple reasons for screening.

### Table 2 BI-RADS interpretation according to screening schedule

| Interpretation       | Stacked (n = 165) | Alternating (n = 206) | P value |
|----------------------|-------------------|-----------------------|---------|
|                      | N (%) [95% CI]    | N (%) [95% CI]        |         |
| BI-RADS 1 or 2       | 133 (80.6%) [73.9, 86.0] | 183 (88.9%) [83.8, 92.5] | 0.027   |
| BI-RADS 3            | 16 (9.7%) [6.0, 15.3]  | 6 (2.9%) [1.2, 6.4]   | 0.006   |
| BI-RADS 4, 5, 0      | 16 (9.7%) [6.0, 15.3]  | 17 (8.3%) [5.1, 12.9] | 0.627   |

Figure 1 Consort diagram for population screened.
Table 3 False positive rates according to schedule

|                  | Overall (n = 371) | Stacked (n = 165) | Alternating (n = 206) | p value |
|------------------|-------------------|-------------------|-----------------------|---------|
| BI-RADS 3*       | 22 (5.9%)         | 16 (9.7%)         | 6 (2.9%)              | 0.006   |
|                  | [39.8, 9]         | [60.0, 15.3]      | [12.2, 6.4]           |         |
| BI-RADS 4, 5, 0  | 29 (7.8%)         | 14 (8.5%)         | 15 (7.3%)             | 0.668   |
|                  | [5.5, 11.0]       | [5.0, 13.8]       | [4.4, 11.8]           |         |
| BI-RADS 3, 4, 5, 0| 51 (13.7%)       | 30 (18.2%)        | 21 (10.2%)            | 0.026   |
|                  | [10.6, 17.6]      | [13.0, 24.8]      | [6.7, 15.1]           |         |
| BI-RADS 3, 4, 5, 0| 31 (24.6%)       | 20 (27.4%)        | 11 (20.8%)            | 0.393   |
| For baseline MRI | 17.9 (3.28)       | 18.4 (3.86)       | 11.8 (33.6)           |         |
| BI-RADS 3, 4, 5, 0| 20 (8.2%)        | 10 (10.9%)        | 10 (6.5%)             | 0.230   |
| For subsequent MRI| 5.3 (12.3)      | 5.8 (19.0)        | 3.5 (11.8)            |         |
| Benign biopsy    | 22 (5.9%)         | 10 (6.1%)         | 12 (5.8%)             | 0.92    |
|                  | [3.9, 8.9]        | [3.2, 10.9]       | [3.3, 10.0]           |         |

*p value compares stacked to alternating schedule.
**Numbers in parentheses are percentages, and numbers in square brackets are the 95% Agresti-Coull confidence intervals for the percentage.

Discussion

In this retrospective evaluation of a prospectively gathered cohort we have shown similar rates of false positive studies regardless of the screening schedule or definition of a positive study. To our knowledge, this is one of the first studies to compare the two styles of screening in a prospectively gathered cohort and one of the largest series to examine the alternating schedule of mammogram and screening breast MRI. Le-Petross et al. reported their institutional practice of alternating studies and found a sensitivity of 92% and a specificity of 79%; similar to published series with studies performed annually (Brekelmans et al. 2001) (Krieger et al. 2001) (Tilanus-Linthorst et al. 2000) (Krieger et al. 2004) (Weinstein et al. 2009) (Klijn 2010) (Kuhl et al. 2005) (Warner et al. 2004) (Leach et al. 2005). While their study suggests that imaging performed on an alternating schedule has similar sensitivity and specificity to imaging performed on a stacked schedule, they did not compare the two strategies. One additional study suggests that alternating imaging is a more cost efficient strategy, especially for BRCA1 carriers, largely related to the high incidence of cancer (Cott Chubiz et al. 2013) (Lowry et al. 2012).

In our cohort false-positive rates were influenced by both the type of examination and the definition of a positive study. We observed a higher overall false positive rate for baseline screening MRI compared to subsequent examination (24.8% vs 9.5%) as highlighted in Table 3. Higher false-positive rates for baseline compared to subsequent mammograms have been reported (Frankel et al. 1995) (Burnside et al. 2002) (Callaway et al. 1997). Only one study has examined this issue for screening MRI (Abramovici & Mainiero 2011). Using data from the Dutch MRI Screening (MRISC) study the false positive rate for the baseline screening breast MRI was 14% which decreased to 8.2% with subsequent rounds of screening. We did not find a significant difference between false-positive rates for baseline or subsequent examinations based on schedule.

We did observe a significant difference in false-positive rates depending on the definition of a positive study (BI-RADS 4, 5, 0 vs BI-RADS 3, 4, 5, 0 or biopsy). We found the highest false-positive rate when considering BI-RADS 3 category MRI.

Table 4 Characteristics of breast cancers diagnosed in cohort

| Preceding MRI type | MRI BI-RADS category | MRI cycle # | Biopsy result | Breast cancer risk factor |
|--------------------|----------------------|-------------|---------------|--------------------------|
| Stacked            | 4                    | 1           | 0.8 cm MD IDC, LN -, ER/PR+, HER 2- | Hx of LCIS |
| Alternating        | 5                    | 3           | 0.7 cm MD ILC, LN-, ER/PR+, HER 2- | BRCA 2 carrier |
| Alternating        | 0                    | 5           | 0.6 cm MD ILC, LN-, ER+, PR+ | BRCA 2 carrier |
| Interval cancer    | 5                    |             | 2.4 cm PD IDC, LN+, ER+, PR, HER 2- | BRCA 1 carrier |

Abbreviations: MD = moderately differentiated, PD = poorly differentiated, IDC = infiltrating ductal carcinoma, ILC = infiltrating lobular carcinoma, LN = lymph node, ER = estrogen receptor, PR = progesterone receptor.
3, 4, 5, 0 as a positive study (13.7%), with much lower rates of false-positive studies for BI-RADS 4, 5, 0 (7.8%) and for benign biopsy (5.9%). The higher rate when calling BI-RADS 3, 4, 5, 0 positive can be explained by BI-RADS 3 interpretations. In our cohort there were no cancers identified within one year of any BI-RADS 3 MRI. Others have shown similarly high rates of false positive screening breast MRI when including BI-RADS 3 interpretations as positive, with a range between 6.3 – 27% in published studies (Bahrs et al. 2014) (Eby et al. 2009) (Liberman et al. 2003) (Weinstein et al. 2010) (Eby et al. 2007) (Hauth et al. 2010) (Kuhl et al. 2005) (Rosen et al. 2002) (Barr et al. 2013). The high rate of BI-RADS 3 lesions and low likelihood of malignancy associated with a BI-RADS 3 lesion for any breast screening modality (MRI, mammogram or ultrasound) has prompted some to suggest that short-interval follow-up may not be needed for this group (Bahrs et al. 2014) (Barr et al. 2013) (Varas et al. 2002) (Vizcaino et al. 2001).

The number of cancers identified in our population is quite small, likely due to the broader definition of "high risk" and short follow-up time. Three of the four cancers were identified by screening and these were all lymph node negative and less than 1 cm (Table 4). There was one interval cancer in a BRCA1 carrier which was lymph node positive and >2 cm. This low rate of interval cancers is similar to other studies combining screening breast MRI with annual mammography (Krieger et al. 2004) (Warner et al. 2004) (Kuhl et al. 2005) (Sardanelli et al. 2011). Similar to Warner et al. we have shown that screening with MRI is associated with identification of lower risk cancers (Warner et al. 2011) (Gareth et al. 2014).

This study has weaknesses that must be considered. Women in this study were not randomized to a screening schedule and there is likely some selection bias to the choices made for screening schedule. The cohort is heterogeneous with respect to breast cancer risk; including women with BRCA mutations, women with strong family histories and women who had a biopsy showing atypia. Despite these weaknesses this study has several strengths. This is the largest cohort to date reporting screening on different schedules. Le-Petross et al. studied 73 women with BRCA1 and BRCA2 mutations who were getting every 6 month (alternating) screening only (Le-Petross et al. 2011). In our cohort of high risk women the decision of which schedule to adhere to (alternating or stacked) was made by the provider and patient, making it similar to a real –world experience. The majority of women (71%) kept to the chosen schedule through multiple rounds of screening; despite the fact that this population is young and largely (79%) premenopausal.

In conclusion, we have shown that the false-positive rates are similar for studies performed on either a stacked or alternating schedules regardless of the definition of a false-positive study. This finding and information from prior studies (Le-Petross et al. 2011) showing similar sensitivity for alternating schedules, suggests that high risk women and their providers may choose the schedule they prefer when screening with annual MRI and mammogram. This is important as there is not likely to be a randomized clinical trial comparing the two schedules given the high cost and large number of women needed for such a study.

Competing interests
The authors declare that they have no competing interests.

Authors' contributions
EO participated in conception and design, collection and assembly of data, data analysis and interpretation and manuscript writing. JW participated in conception and design and data analysis and interpretation. BS participated in conception and design and data analysis and interpretation. TR participated in collection in and assembly of data and manuscript writing. YJ participated in data analysis and interpretation. MW participated in conception and design, data analysis and interpretation and manuscript writing. All authors read and approved the final manuscript.

Acknowledgments
Funding Sources: Brian Sprague and Jue Wang: U54 CA163303.

Author details
1 Department of Medicine, University of Vermont, Burlington, VT, USA.
2 Division of Biostatistics, University of Texas Health Science Center, Austin, TX, USA.
3 Department of Surgery, Vermont Cancer Center, University of Vermont, Burlington, VT, USA.
4 Department of Radiology, University of Vermont, Burlington, VT, USA.

Received: 29 December 2014 Accepted: 5 January 2015
Published online: 13 February 2015

References
Abromovici G, Mainiero MB (2011) Screening breast MR imaging: comparison of interpretation of baseline and annual follow-up studies. Radiology 259(1):85–91, doi:10.1148/radiol.10101009
Bahrs SD, Baur A, Hattermann V, Hohn M, Vogel U, Claussen CD, Siegmann-Luz KC (2014) BI-RADS(R) 3 lesions at contrast-enhanced breast MRI is an initial short-interval follow-up necessary? Acta Radiol 55(3):260–265, doi:10.1177/0284185113501304
Barr RG, Zhang Z, Cormack JB, Mendelson EB, Berg WA (2013) Probably benign lesions at screening breast US in a population with elevated risk: prevalence and rate of malignancy in the ACRIN 6666 trial. Radiology 269(3):701–712, doi:10.1148/radiol.13122829
Berg WA, Blume JD, Cormack JB, Mendelson EB, Leher D, Bohm-Velez M, Investigators A (2008) Combined screening with ultrasound and mammography vs mammography alone in women at elevated risk of breast cancer. JAMA 299(18):2151–2163, doi:10.1001/jama.299.18.2151
Brekelmans CT, Seynaeve C, Bartels CC, Tilanus-Linthorst M, Meijers-Heijboer EJ, Crepin CM, Genetic C (2001) Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk. J Clin Oncol 19(4):924–930
Burnside ES, Sickles EA, Sohlich RE, Dee KE (2002) Differential value of comparison with previous examinations in diagnostic versus screening mammography. AJR Am J Roentgenol 179(5):1173–1177, doi:10.2214/ajr.179.5.1791173
Callaway MP, Boggis CR, Astley SA, Hutt I (1997) The influence of previous films on screening mammographic interpretation and detection of breast carcinoma. Clin Radiol 52(7):527–529
Cott Chubiz JE, Lee YM, Gilmore ME, Kong CY, Lowry KP, Halpern EF, Gazelle GS (2013) Cost-effectiveness of alternating magnetic resonance imaging and
digital mammography screening in BRCA1 and BRCA2 gene mutation carriers. Cancer 119(6):1266–1276, doi:10.1002/cncr.27864

Eby PR, Demartini WB, Peacock S, Rosen EL, Laub B, Lehman CD (2007) Cancer yield of probably benign breast MR examinations. J Magn Reson Imaging 26(4):955–959, doi:10.1002/jmri.21123

Eby PR, DeMartini WB, Gutierrez RL, Saini MH, Peacock S, Lehman CD (2009) Characteristics of probably benign breast MRI lesions. AJR Am J Roentgenol 193(3):861–867, doi:10.2214/AJR.08.2066

Frankel SD, Sickles EA, Curpen BN, Sollitto RA, Ominsky SH, Galvin HB (1995) Initial versus subsequent screening mammography: comparison of findings and their prognostic significance. AJR Am J Roentgenol 164(5):1107–1109, doi:10.2214/ajr.164.5.7717214

Gareth ED, Nisha K, Yit L, Soujanye G, Emma H, Massat NJ, Stephen D (2014) MRI breast screening in high-risk women: cancer detection and survival analysis. Breast Cancer Res Treat 153(3):663–672, doi:10.1007/s10549-014-2931-9

Hauth E, Umutlu L, Kummel S, Kimmig R, Forsting M (2010) Follow-up of probably benign lesions (BI-RADS 3 category) in breast MR imaging. Breast J 16(3):297–304, doi:10.1111/j.1524-4741.2010.00916.x

Hendrick RE, Smith RA, Rutledge JH, 3rd, Smart CR. Benefit of screening mammography in women aged 40–49: a new meta-analysis of randomized controlled trials. J Natl Cancer Inst Monogr. 1997;22:87–92.

Kerlikowske K, Grady D, Barclay J, Sickles EA, Eaton A, Emst V (1993) Positive predictive value of screening mammography by age and family history of breast cancer. JAMA 270(20):2444–2450

Klijn JG (2010) Early diagnosis of hereditary breast cancer by magnetic resonance imaging: what is realistic? J Clin Oncol 28(9):1441–1445, doi:10.1200/JCO.2009.26.3467

Kriege M, Brekelmans CT, Boetes C, Rutgers EJ, Klijn JG (2001) MRI screening for breast cancer in women with familial or genetic predisposition: design of the Dutch National Study (MRISC). Fam Cancer 1(3–4):163–168

Kriege M, Brekelmans CT, Boetes C, Bovers PE, Zonderland HM, Oudejijn IM, Magnetic Resonance Imaging Screening Study, G (2004) Efficacy of MR and mammography for breast cancer screening in women with a familial or genetic predisposition. N Engl J Med 351(5):427–437, doi:10.1056/NEJMoa031759

Kuhl CK, Schrading S, Leutner CC, Morakabati-Spitz N, Wardelmann E, Fimmers R, Juhl J (2005) Mammography, breast ultrasound, and magnetic resonance imaging: findings from ACRIN 6667. Radiology 233(3):849–847, doi:10.1148/radiol.233304490

Leach MO, Boggis CR, Dixon AK, Easton DF, Eeles RA, Evans DG, group, M. s (2005) Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet 365(9473):1769–1778, doi:10.1016/S0140-6736(05)66481-1

Le-Petross HT, Whitman GJ, Atchley DP, Yuan Y, Gutierrez-Barrera A, Hortobagyi GN, Arun BK (2011) Effectiveness of alternating mammography and magnetic resonance imaging for screening women with deleterious BRCA mutations at high risk of breast cancer. Cancer 117(17):3900–3907, doi:10.1002/cncr.25971

Liberman L, Morris EA, Benton CL, Abramson AF, Dershaw DD (2003) Probably benign lesions at breast magnetic resonance imaging: preliminary experience in high-risk women. Cancer 98(2):377–388, doi:10.1002/cncr.11491

Lowry KP, Lee JM, Kong CY, McMahon PM, Gilmore ME, Cott Chubiz JE, Gazelle GS (2012) Annual screening strategies in BRCA1 and BRCA2 gene mutation carriers: a comparative effectiveness analysis. Cancer 118(8):2021–2030, doi:10.1002/cncr.26424

Rosen G, Baker JA, Soo MS (2002) Malignant lesions initially subjected to short-term mammographic follow-up. Radiology 223(1):221–228, doi:10.1148/radiol.2231011355

Sardanelli F, Podo F, Santoro F, Manoukian S, Bergonzini S, Trecate G, High Breast Cancer Risk Italian, S (2011) Multicenter surveillance of women at high genetic breast cancer risk using mammography, ultrasonography, and contrast-enhanced magnetic resonance imaging (the high breast cancer risk Italian 1 study): final results. Invest Radiol 46(2):94–105, doi:10.1097/RLI0b013e3181f5c6f

Sawlow D, Boetes C, Burke W, Hamms S, Leach MO, Lehman CD, Russell CA (2007) American Cancer Society guidelines for breast screening with MR as an adjunct to mammography. CA Cancer J Clin 57(2):75–89

Tilanus-Linthorst MW, Obdeijn IM, Bartels KC, de Koning HJ, Oudkerk M (2000) First experiences in screening women at high risk for breast cancer with MR imaging. Breast Cancer Res Treat 63(1):53–60

Varas X, Leborgne JH, Leborgne F, Mezzeira J, Jaumandreu S, Leborgne F (2002) Revisiting the mammographic follow-up of BI-RADS category 3 lesions. AJR Am J Roentgenol 179(3):691–695, doi:10.2214/ajr.179.3.1790691

Viccario I, Gadea I, Andreu L, Sales D, Ruiz-Peralta F, Cuevas D, Screening Program Working G (2001) Short-term follow-up results in 795 nonpalpable probably benign lesions detected at screening mammography. Radiology 219(2):475–483, doi:10.1148/radiology.219.2.01ma11475

Warner E, Plewes DB, Hill KA, Causer PA, Zubovits JT, Jong RA, Narod SA (2004) Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA 292(11):1317–1325, doi:10.1001/jama.292.11.1317

Warner E, Hill K, Causer P, Plewes D, Jong R, Yaffe M, Narod SA (2011) Prospective study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging. J Clin Oncol 29(1):1664–1669, doi:10.1200/JCO.2009.27.0835

Weinstein SP, Locako AR, Conant EF, Rosen M, Thomas KM, Schnall MD (2009) Multimodality screening of high-risk women: a prospective cohort study. J Clin Oncol 27(36):6124–6128, doi:10.1200/JCO.2009.24.4277

Weinstein SP, Hanna LG, Gatschon C, Schnall MD, Rosen MA, Lehman CD (2010) Frequency of malignancy seen in probably benign lesions at contrast-enhanced breast MR imaging: findings from ACRIN 6667. Radiology 255(3):731–737, doi:10.1148/radiol.10081712